Combination of AAV-CCL19 and GPC3 CAR-T Cells in the Treatment of Hepatocellular Carcinoma
Background. Chimeric antigen receptor-modified T cell (CAR-T) therapy has great potential for treating malignant tumors, especially hematological malignancies. However, the therapeutic effect of solid tumors is limited. One of the most important factors is the homing of CAR-T cells to tumor tissues...
Saved in:
Main Authors: | Min Meng, Yi-chen Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-01-01
|
Series: | Journal of Immunology Research |
Online Access: | http://dx.doi.org/10.1155/2021/1782728 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The molecular receptor NKBB enhances the persistence and anti-hepatocellular carcinoma activity of GPC3 CAR-T cells
by: Minghao Sui, et al.
Published: (2025-02-01) -
Preclinical optimization of a GPC2-targeting CAR T-cell therapy for neuroblastoma
by: Nan Li, et al.
Published: (2023-01-01) -
Exploring Glypican-3 targeted CAR-NK treatment and potential therapy resistance in hepatocellular carcinoma.
by: Lei Yang, et al.
Published: (2025-01-01) -
Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma
by: Wei Gao, et al.
Published: (2021-04-01) -
Multiplex immunohistochemistry to explore the tumor immune microenvironment in HCC patients with different GPC3 expression
by: Mingzhen Zhou, et al.
Published: (2025-01-01)